Yposkesi Acquisition Fuels SK's Global Push Into Biologics Manufacturing
Adds Gene, Cell Therapy Capabilities
South Korean conglomerate SK Group continues its cross-border acquisitions of contract manufacturers, this time of French biologics specialist Yposkesi, marking a new push into the gene and cell therapy sector as it looks to become a global leader in the production of both innovative chemical drugs and biologics.
